Skip to main content


Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Fig. 1 | Arthritis Research & Therapy

Fig. 1

From: Therapeutic effect of a novel histone deacetylase 6 inhibitor, CKD-L, on collagen-induced arthritis in vivo and regulatory T cells in rheumatoid arthritis in vitro

Fig. 1

Therapeutic effects of CKD-L on CIA mice. After the onset of arthritis, mice were treated with vehicle, Tubastatin A (30 mg/kg), or CKD-L (15 or 30 mg/kg) subcutaneously every day for 18 days after the second immunization. CKD-L (30 mg/kg) and Tubastatin A significantly decreased arthritis score compared to vehicle (a). Body weight did not change during drug administration (b). The changes in body weight between day 21 and day 38 was not significantly different among the groups (c). *p < 0.05, **p < 0.01, vs vehicle

Back to article page